Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

AstraZeneca ( AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K.

Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

The DISCUS trial demonstrated improved QOL with 3 cycles of chemotherapy compared to 6 cycles in advanced urothelial cancer patients. Both treatment arms showed similar overall survival and ...